These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30773984)

  • 1. Gene mutations do not operate in a vacuum: the increasing importance of epigenetics in juvenile myelomonocytic leukemia.
    Flotho C
    Epigenetics; 2019 Mar; 14(3):236-244. PubMed ID: 30773984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia.
    Hashmi SK; Punia JN; Marcogliese AN; Gaikwad AS; Fisher KE; Roy A; Rao P; Lopez-Terrada DH; Ringrose J; Loh ML; Niemeyer CM; Rau RE
    Pediatr Blood Cancer; 2019 Oct; 66(10):e27905. PubMed ID: 31250550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole Genome MBD-seq reveals different CpG methylation patterns in Azacytidine-treated Juvenile Myelomonocytic Leukaemia (JMML) patients.
    Leoncini PP; Vitullo P; Di Florio F; Tocco V; Cefalo MG; Pitisci A; Girardi K; Niemeyer C; Locatelli F; Bertaina A
    Br J Haematol; 2018 Sep; 182(6):909-912. PubMed ID: 28771681
    [No Abstract]   [Full Text] [Related]  

  • 4. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Flotho C; Sommer S; Lübbert M
    Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia.
    Fluhr S; Boerries M; Busch H; Symeonidi A; Witte T; Lipka DB; Mücke O; Nöllke P; Krombholz CF; Niemeyer CM; Plass C; Flotho C
    Clin Epigenetics; 2016; 8():50. PubMed ID: 27158276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia.
    Rudelius M; Weinberg OK; Niemeyer CM; Shimamura A; Calvo KR
    Virchows Arch; 2023 Jan; 482(1):113-130. PubMed ID: 36445482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.
    Caye A; Strullu M; Guidez F; Cassinat B; Gazal S; Fenneteau O; Lainey E; Nouri K; Nakhaei-Rad S; Dvorsky R; Lachenaud J; Pereira S; Vivent J; Verger E; Vidaud D; Galambrun C; Picard C; Petit A; Contet A; Poirée M; Sirvent N; Méchinaud F; Adjaoud D; Paillard C; Nelken B; Reguerre Y; Bertrand Y; Häussinger D; Dalle JH; Ahmadian MR; Baruchel A; Chomienne C; Cavé H
    Nat Genet; 2015 Nov; 47(11):1334-40. PubMed ID: 26457648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7.
    Furlan I; Batz C; Flotho C; Mohr B; Lübbert M; Suttorp M; Niemeyer CM
    Blood; 2009 Mar; 113(12):2867-8. PubMed ID: 19299654
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.
    Locatelli F; Algeri M; Merli P; Strocchio L
    Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
    Niemeyer CM; Flotho C
    Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated molecular profiling of juvenile myelomonocytic leukemia.
    Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H
    Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia.
    Wilhelm T; Lipka DB; Witte T; Wierzbinska JA; Fluhr S; Helf M; Mücke O; Claus R; Konermann C; Nöllke P; Niemeyer CM; Flotho C; Plass C
    Epigenetics; 2016; 11(2):110-9. PubMed ID: 26891149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.
    Lipka DB; Witte T; Toth R; Yang J; Wiesenfarth M; Nöllke P; Fischer A; Brocks D; Gu Z; Park J; Strahm B; Wlodarski M; Yoshimi A; Claus R; Lübbert M; Busch H; Boerries M; Hartmann M; Schönung M; Kilik U; Langstein J; Wierzbinska JA; Pabst C; Garg S; Catalá A; De Moerloose B; Dworzak M; Hasle H; Locatelli F; Masetti R; Schmugge M; Smith O; Stary J; Ussowicz M; van den Heuvel-Eibrink MM; Assenov Y; Schlesner M; Niemeyer C; Flotho C; Plass C
    Nat Commun; 2017 Dec; 8(1):2126. PubMed ID: 29259247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome.
    Lasho T; Patnaik MM
    Best Pract Res Clin Haematol; 2020 Jun; 33(2):101171. PubMed ID: 32460983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Two Juvenile Myelomonocytic Leukemia Patients According to Clinical and Genetic Features.
    Tüfekçi Ö; Ören H; Demir Yenigürbüz F; Gözmen S; Karapınar TH; İrken G
    Turk J Haematol; 2015 Jun; 32(2):175-9. PubMed ID: 26316488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.
    Niemeyer CM; Flotho C; Lipka DB; Starý J; Rössig C; Baruchel A; Klingebiel T; Micalizzi C; Michel G; Nysom K; Rives S; Schmugge Liner M; Zecca M; Schönung M; Baumann I; Nöllke P; Benettaib B; Biserna N; Poon J; Simcock M; Patturajan M; Menezes D; Gaudy A; van den Heuvel-Eibrink MM; Locatelli F
    Blood Adv; 2021 Jul; 5(14):2901-2908. PubMed ID: 34297046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational landscape of Juvenile Myelomonocytic Leukemia (JMML)-A real-world context.
    Nathany S; Chatterjee G; Ghai S; Moulik NR; Shetty D; Subramanian PG; Tembhare P; Gujral S; Dhamne C; Banavali S; Narula G; Patkar N
    Int J Lab Hematol; 2021 Dec; 43(6):1531-1538. PubMed ID: 34387930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia.
    Schönung M; Meyer J; Nöllke P; Olshen AB; Hartmann M; Murakami N; Wakamatsu M; Okuno Y; Plass C; Loh ML; Niemeyer CM; Muramatsu H; Flotho C; Stieglitz E; Lipka DB
    Clin Cancer Res; 2021 Jan; 27(1):158-168. PubMed ID: 33139265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia.
    Hecht A; Meyer J; Chehab FF; White KL; Magruder K; Dvorak CC; Loh ML; Stieglitz E
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27948. PubMed ID: 31347788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment.
    Leoncini PP; Bertaina A; Papaioannou D; Flotho C; Masetti R; Bresolin S; Menna G; Santoro N; Zecca M; Basso G; Nigita G; Veneziano D; Pagotto S; D'Ovidio K; Rota R; Dorrance A; Croce CM; Niemeyer C; Locatelli F; Garzon R
    Oncotarget; 2016 Aug; 7(34):55395-55408. PubMed ID: 27447965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.